Syndax Pharmaceuticals SNDX Payments to Acquire Short-Term Investments
Payments to Acquire Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's payments to acquire short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's payments to acquire short-term investments?
- Syndax Pharmaceuticals (SNDX) reported payments to acquire short-term investments of $39.39M in Q1 2026.
- How has Syndax Pharmaceuticals's payments to acquire short-term investments changed year-over-year?
- Syndax Pharmaceuticals's payments to acquire short-term investments increased by 273.8% year-over-year, from $10.54M to $39.39M.
- What is the long-term trend for Syndax Pharmaceuticals's payments to acquire short-term investments?
- Over 4 years (2021 to 2025), Syndax Pharmaceuticals's payments to acquire short-term investments has grown at a -9.7% compound annual growth rate (CAGR), from $294.72M to $195.81M.